CWY

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

Retrieved on: 
금요일, 12월 9, 2022
MEAI, American Seed Trade Association, Food industry, Pharmacy, Health, MDXX, FSE, CWY, CSE, Research, Patent, Therapy, Medical device, Pharmaceutical industry, Kadysh

VANCOUVER, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment of seasoned regulatory executive Nicholas Kadysh as special advisor for the development of MEAI as an alcohol substitute.

Key Points: 
  • Kadysh, a former executive at Red Bull Canada and Juul Labs Canada, is a career expert on navigating complex regulatory challenges in the health and food industry.
  • We are thrilled to have him join the company and contribute from his vast experience to our alcohol substitute program," said Dr. Adi Zuloff- Shani, Clearmind's Chief Executive Officer.
  • In parallel to developing its innovative novel psychedelic-derived drug candidate MEAI for treating addictions, Clearmind is also building a parallel track in which MEAI is deployed as an alcohol substitute.
  • The company’s primary objective is to research and develop psychedelic-based compounds and commercialize them as regulated medicine, foods or supplements.

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Retrieved on: 
수요일, 11월 23, 2022
FIH, CWY, Food, Safety, Acquisition, AUD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FSE, GMP, Patent, Good, Death, Research, Therapy, CSE, Clinical trial, New Drug Application, FDA, MEAI, Pharmaceutical industry

Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.

Key Points: 
  • Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
  • The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound.
  • "Clearmind continues its progress toward FIH clinical trial" said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
  • "Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition. "